Having trouble accessing articles? Reset your cache.

With $22M B round, OncoCell to launch prostate cancer test

With its $22.2 million series B round, OncoCell plans to launch next summer the first blood test from its diagnostic platform based on immune gene expression profiles.

Mark McDonough,

Read the full 280 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE